Science and Technology
Source : (remove) : Healio
RSS • JSON • XML • CSV
Science and Technology
Source : (remove) : Healio
RSS • JSON • XML • CSV

FDA recap: First new treatment for stroke in 3 decades, generic rivaroxaban and more


  Copy link into your clipboard //science-technology.news-articles.net/content/2 .. e-in-3-decades-generic-rivaroxaban-and-more.html
  Print publication without navigation Published in Science and Technology on by Healio
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source


  The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug for the management of a rare lipid disease.In addition, semaglutide (Ozempic,

The article from Healio discusses several key updates in cardiology from the FDA. Firstly, the FDA approved tenecteplase (TNKase) for the treatment of acute ischemic stroke, marking the first new treatment for this condition in over three decades. This approval expands the use of tenecteplase, which was previously only approved for acute myocardial infarction. Additionally, the FDA has approved a generic version of the anticoagulant rivaroxaban (Xarelto), which is expected to increase access to this medication for preventing and treating blood clots. The article also touches on other FDA actions, including the approval of a new drug for heart failure with preserved ejection fraction, and updates on labeling changes for existing cardiovascular drugs. These developments signify significant advancements in the management of cardiovascular diseases, offering new treatment options and potentially more affordable alternatives.

Read the Full Healio Article at:
[ https://www.healio.com/news/cardiology/20250327/fda-recap-first-new-treatment-for-stroke-in-3-decades-generic-rivaroxaban-and-more ]

Publication Contributing Sources